Myriad Genetics, a leader in molecular diagnostic testing and precision medicine, has expanded its MyRisk® Hereditary Cancer Test—the gold standard in germline testing—to include additional genes referenced in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and recommendations from the American Society of Clinical Oncology (ASCO).
These newly added genes are strongly associated with hereditary cancer risk and offer clear clinical actionability. With this update, the MyRisk panel now comprises 63 carefully selected genes across more than 11 cancer types, reflecting Myriad’s continued focus on delivering meaningful insights that support evolving clinical needs.
“While many labs can detect DNA variants, it’s the interpretation of those variants that truly impacts patient care and that is where Myriad excels,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. “Medical societies recommend genes for testing when they influence treatment decisions, and those are the genes we prioritize in the MyRisk Test. I’m delighted that these clinically significant genes are now part of the core MyRisk panel. As guidelines evolve, Myriad remains committed to providing clinicians and genetic counselors with insights of high clinical utility to guide patient care.”
The MyRisk Test is designed to provide clinical value throughout the cancer care continuum—from treatment decision-making to surveillance planning and family risk assessment. Clinicians can order and access the expanded MyRisk results through paper Test Requisition Forms, the Myriad patient portal, and supported EMR systems including EPIC and OncoEMR. The full gene list and medical management recommendations can be viewed in the Myriad gene table.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Also Read
